Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Isotretinoin
Therapeutic Area : Dermatology
Study Phase : Phase II
Recipient : Timber Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Merger
Timber Pharmaceuticals Announces Merger Closing
Details : The combined company will have a robust pipeline including Timber's two Phase 2b programs and a preclinical program targeting multiple niche orphan indications with no approved treatments as well as BioPharmX's two Phase 3-ready topical minocycline progr...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 18, 2020
Lead Product(s) : Isotretinoin
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Recipient : Timber Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Isotretinoin
Therapeutic Area : Dermatology
Study Phase : Phase II
Recipient : Timber Pharmaceuticals
Deal Size : $20.0 million
Deal Type : Merger
BioPharmX And Timber Pharmaceuticals Announce Entry into Merger Agreement
Details : Under the terms of the merger agreement, a wholly-owned subsidiary of BioPharmX will be merged with and into Timber, with Timber surviving the merger as a wholly-owned subsidiary of BioPharmX.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 28, 2020
Lead Product(s) : Isotretinoin
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Recipient : Timber Pharmaceuticals
Deal Size : $20.0 million
Deal Type : Merger
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 12, 2018
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Open Label Phase 2 Feasibility Study of BPX-04 Topical Minocycline Gel in Rosacea
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 10, 2017
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Open Label Photo-Documentation Study Of BPX-01 Minocycline Gel
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 27, 2016
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 28, 2016
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BPX-01
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 15, 2016
Lead Product(s) : BPX-01
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 01, 2016
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Violet Molecular Iodine (I2)
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 08, 2016
Lead Product(s) : Violet Molecular Iodine (I2)
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable